Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorChang Gung Memorial Hospital
About this trial
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
Eligibility criteria
Qualifiers
Aged between 18 and 90 years.
Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).
Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.
Willing to continue follow-up visits at the hospital after completion of treatment.
Disqualifiers
Presence of psychiatric disorders.
Deemed unsuitable for participation by the attending physician.
Unwilling to participate in the study.
Trial design
Treatments tested in this trial
- low-dose oral chemotherapy
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov